Recently, Suzhou Venmed Technology Co., Ltd. (referred to as "Venmedtech"), a leading enterprise in China's venous interventional device industry, completed an equity financing of tens of millions of yuan, exclusively invested by Chuangjing Capital, with WinX Capital serving as the exclusive financial advisor. It is reported that this round of financing will be used to solidify the technical barriers in venous intervention, accelerate the R&D and commercialization of innovative pipelines such as peripheral arteries and tumor embolization, and deepen the entire industrial chain layout of "devices + materials + supply chain."
Venmedtech was founded in 2016, precisely targeting the core diagnostic and treatment needs of over 160 million patients suffering from deep vein thrombosis, iliac vein compression syndrome, and lower extremity arterial sclerosis occlusion. It has currently achieved 100% full coverage of peripheral venous disease devices and established a one-stop diagnosis and treatment solution covering peripheral veins, peripheral arteries, tumor embolization, and interventional access. The company has accumulated more than 90 domestic and international patents.
The core product, Venastent? Iliac Vein Stent System, is the only domestically produced brand in China that has been certified through a strict RCT randomized controlled clinical trial. With four major innovations—large crown design, segmented open-closed loop structure, three-row imaging markers for positioning, and thin-walled stents—it effectively addresses clinical pain points. The market share of this domestically produced brand ranks steadily among the top tier in China, with sales increasing exponentially each year.
Venmedtech Iliac Vein Stent (Innovation 1: Large Coronary Design; Innovation 2: Segmented Open-Closed Loop Stent Design; Innovation 3: Triple-Row Marking for More Accurate Positioning; Innovation 4: Thin-Wall Stent Design)
On the commercialization level, the company has built an efficient sales network covering all of China, with hundreds of agents and coverage of over a thousand hospitals as of 2025. Amidst the normalization of centralized procurement, the iliac vein stent successfully won the bid for Group A of the centralized procurement, ranking first in reported volume for domestically produced products; both above-the-knee and below-the-knee arterial occlusion products for the lower limbs have been approved, forming a "vein + artery" dual-growth pattern.
At the supply chain level, the company has built three major platforms: device R&D, innovative materials, and upstream/downstream supply chains. It has also stockpiled innovative achievements such as alginate oligosaccharides and biodegradable embolic microspheres, ready to be launched, establishing a self-controlled, cost-reducing, and efficiency-enhancing technological ecosystem.
Venmedtech Vein Intervention Device Platform V-Family Overview
In terms of market prospects, peripheral vascular intervention is a high-growth track, with arteries and veins together constituting a billion-dollar market. In China, there are over 130 million patients with peripheral venous diseases. According to Frost & Sullivan, from 2021 to 2030, the number of peripheral venous intervention procedures in China is expected to increase from 201,000 to 1,529,000, with an annual compound growth rate of 25.3%; the number of peripheral arterial intervention procedures is expected to grow from 163,000 to 602,000, with an annual compound growth rate of 15.6%. Due to the slow progression of the disease and the emerging stage of vascular surgery, the current penetration rate of peripheral interventions is less than 1%, indicating significant growth potential.
Technically, arterial devices need to withstand high-speed blood flow impact, while venous devices must balance support and flexibility, with a development difficulty no less than that of arterial devices. In the arterial field, foreign companies still dominate, whereas in the venous field, the localization process is faster, becoming the core breakthrough point for Chinese-produced alternatives.
Today, Venmedtech, with the mission of replacing imported products with domestically produced ones, is addressing clinical needs, focusing on venous intervention, and accelerating its expansion into arterial and tumor embolization fields. After this round of financing, the company will also increase R&D investment, expedite the approval and market promotion of innovative products, complete the layout of the entire industry chain, and drive China's peripheral interventional devices to the global stage.
